−1.6409USD
−47.72 MUSD
27.51 MUSD
8.78 M
About Telesis Bio, Inc.
Sector
CEO
Todd R. Nelson
Website
Headquarters
San Diego
Employees (FY)
147
Founded
2011
ISIN
US1920031010
FIGI
BBG011363VM3
Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TBIO is 0.3530 USD — it has decreased by 7.11% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Telesis Bio, Inc. stocks are traded under the ticker TBIO.
Telesis Bio, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
TBIO stock is 48.94% volatile and has beta coefficient of 2.99. Check out the list of the most volatile stocks — is Telesis Bio, Inc. there?
TBIO earnings for the last quarter are −0.37 USD whereas the estimation was −0.30 USD which accounts for −24.72% surprise. Estimated earnings for the next quarter are −0.24 USD. See more details about Telesis Bio, Inc. earnings.
Telesis Bio, Inc. revenue for the last quarter amounts to 5.56 M USD despite the estimated figure of 7.40 M USD. In the next quarter revenue is expected to reach 7.00 M USD.
Yes, you can track Telesis Bio, Inc. financials in yearly and quarterly reports right on TradingView.
TBIO stock has fallen by 17.91% compared to the previous week, the month change is a 36.05% fall, over the last year Telesis Bio, Inc. has showed a 87.83% decrease.
TBIO net income for the last quarter is −17.69 M USD, while the quarter before that showed −10.63 M USD of net income which accounts for −66.37% change. Track more Telesis Bio, Inc. financial stats to get the full picture.
Today Telesis Bio, Inc. has the market capitalization of 11.44 M, it has decreased by 1.78% over the last week.
No, TBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Telesis Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 147.00 employees. See our rating of the largest employees — is Telesis Bio, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Telesis Bio, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Telesis Bio, Inc. stock shows the sell signal. See more of Telesis Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Telesis Bio, Inc. EBITDA is −31.11 M USD, and current EBITDA margin is −112.86%. See more stats in Telesis Bio, Inc. financial statements.